Serum uric acid <6.0 mg/dL at final visit · people with chronic gout
Febuxostat 80 mg/day may leads to higher serum uric acid <6.0 mg/dL at final visit compared with placebo (low certainty).
1 finding from 1 review
Acute gout attacks · patients with chronic cout
Febuxostat 120 mg/day probably leads to higher incidence of gout flares compared with placebo (moderate certainty).
1 finding from 1 review
Serum uric acid <6.0 mg/dL at final visit · patients with chronic cout
Febuxostat 120 mg/day may leads to higher serum uric acid <6.0 mg/dL at final visit compared with placebo (low certainty).
1 finding from 1 review
Pain · patients with chronic cout
The review found no eligible studies for this question.
1 finding from 1 review
Patient global assessment · patients with chronic cout
The review found no eligible studies for this question.
1 finding from 1 review
Health related quality of life · patients with chronic cout
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events · patients with chronic cout
Febuxostat 120 mg/day showed no clear difference in serious Adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with chronic cout
Febuxostat 120 mg/day showed no clear difference in discontinuations due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Acute gout attacks · people with chronic gout
Febuxostat 120 mg/day showed no clear difference in incidence of gout flares compared with allopurinol (high certainty).
1 finding from 1 review
Serum uric acid <6.0 mg/dL at final visit · people with chronic gout
Febuxostat 120 mg/day probably leads to higher serum uric acid <6.0 mg/dL at final visit compared with allopurinol (moderate certainty).
1 finding from 1 review
Pain · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Patient global assessment · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Health related quality of life · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events · people with chronic gout
Febuxostat 120 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (high certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with chronic gout
Febuxostat 120 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (high certainty).
1 finding from 1 review
Adverse effects · Children (mixed dentition; baseline about 8 years)
1 finding from 1 review
Caries increment (dmfs, primary and permanent teeth combined) · Children (mixed dentition; baseline about 8 years)
1 finding from 1 review
One study (252 children) compared xylitol (7.5 g/day) candy with control (sorbitol) candy over 36 months. The data could not be used in analysis because the authors combined primary/deciduous and permanent teeth and…
1 study · 252 participants
GRADE not reported
Number of infants with a caries increment (dmfs) · Infants (primary teeth)
Xylitol wipes (4.2 g/day) showed no clear difference in number of infants with a caries increment (dmfs) compared with control wipes (no xylitol) (low certainty).
1 finding from 1 review
Adverse effects · Infants (primary teeth)
1 finding from 1 review
Caries increment (DFS) · adults
1 finding from 1 review